Company profile for AUM Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

AUM Biosciences is at the forefront of disrupting the drug development process in oncology, to deliver pioneering and affordable targeted drugs across a broad spectrum of cancers. AUM is focused on developing a robust industry leading pipeline of best-in-class and first-in-class small molecule therapies, leveraging the latest in precision and digital medicine tools. Our core mandate of being biomarker driven, using innovati...
AUM Biosciences is at the forefront of disrupting the drug development process in oncology, to deliver pioneering and affordable targeted drugs across a broad spectrum of cancers. AUM is focused on developing a robust industry leading pipeline of best-in-class and first-in-class small molecule therapies, leveraging the latest in precision and digital medicine tools. Our core mandate of being biomarker driven, using innovative clinical trial designs and utilizing smart data differentiates us from other drug development companies. This enables us to identify innovative, early-stage molecules that can be rapidly progressed into successful

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Singapore
Address
Address
10 Anson Rd #24-16A/B International Plaza
Telephone
Telephone
+65 6808 6034
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more
AUM doses first patient in trial of MSS CRC therapy
AUM doses first patient in trial of MSS CRC therapy

31 May 2023

// CLINICAL TRIALS ARENA

https://www.clinicaltrialsarena.com/news/aum-first-patient-mss-crc/

CLINICAL TRIALS ARENA
31 May 2023

https://www.globenewswire.com/news-release/2023/04/26/2655179/0/en/AUM-Biosciences-to-Participate-in-Inaugural-EF-Hutton-Global-Conference.html

GLOBENEWSWIRE
26 Apr 2023

https://www.globenewswire.com//news-release/2023/01/05/2583667/0/en/AUM-Biosciences-Receives-U-S-FDA-Rare-Pediatric-Disease-Designation-for-AUM302-for-Treatment-of-Neuroblastoma.html

GLOBENEWSWIRE
05 Jan 2023

https://www.globenewswire.com//news-release/2022/11/30/2564921/0/en/AUM-Biosciences-Receives-FDA-Orphan-Drug-Designation-for-AUM302-for-the-Treatment-of-Neuroblastoma.html

GLOBENEWSWIRE
30 Nov 2022

https://www.globenewswire.com/news-release/2022/11/15/2556081/0/en/AUM-Biosciences-Receives-Human-Research-Ethics-Committee-Approval-to-Commence-Phase-II-Clinical-Trial-of-AUM001-for-Treatment-of-Metastatic-Colorectal-Cancer-in-Australia.html

GLOBENEWSWIRE
15 Nov 2022

https://www.globenewswire.com/news-release/2022/11/04/2548762/0/en/AUM-Biosciences-to-Participate-in-BioCentury-BayHelix-East-West-BioPharma-Summit.html

GLOBENEWSWIRE
04 Nov 2022

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty